Early Access to Medicines Scheme - Information for Applicants

AI Summary

This guidance from the UK Medicines and Healthcare products Regulatory Agency (MHRA) details the application process for the Promising Innovative Medicine (PIM) designation, the first step of the Early Access to Medicines Scheme (EAMS). The scheme enables patients with life-threatening or seriously debilitating conditions to access innovative treatments before formal marketing authorization. While no specific company is the subject of this guidance, it applies to all pharmaceutical applicants seeking early market entry in the UK. The regulatory framework is established under the Human Medicines Regulations 2012, particularly Regulation 167G. To receive a designation, products must meet three criteria: addressing a high unmet need, offering a major advantage over current UK treatments, and maintaining a favorable risk-benefit profile. Required actions for companies include submitting a formal PIM template, attending a scientific designation meeting, and providing a 20-minute technical presentation. Following designation, companies must submit a Risk Management Plan and adhere to strict pharmacovigilance obligations. Main compliance issues involve the mandatory reporting of serious adverse reactions within 15 days and non-serious reactions within 90 days. Furthermore, companies must notify the MHRA of any emerging safety issues within three working days and submit periodic safety reports every three months during the first year. Failure to maintain these standards or report significant new risks may lead to the immediate withdrawal of the scientific opinion.